The market expects BioHarvest Sciences Inc. (BHST) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to ...

Group 1 - Adaptive Biotechnologies (ADPT) is outperforming its peers in the Medical sector, gaining about 47% year-to-date compared to the sector's average loss of 4.8% [4] - The Zacks Rank for Adaptive Biotechnologies is 2 (Buy), indicating a positive earnings outlook and strong analyst sentiment, with a 5.5% increase in the consensus estimate for full-year earnings [3][4] - The Medical group ranks 3 within the Zacks Sector Rank, which evaluates 16 different sector groups based on the average Zacks Rank of individual stocks [2] Group 2 - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 8% this year, further highlighting ADPT's strong performance [6] - Another outperforming stock in the Medical sector is Centene (CNC), which has gained 3.9% year-to-date, with a Zacks Rank of 2 (Buy) and a 4.4% increase in the consensus EPS estimate [5][7] - The Medical - HMOs industry, where Centene belongs, has experienced a decline of 14% since the beginning of the year, contrasting with the performance of Adaptive Biotechnologies [7]

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 312.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.75 per share when it actually produced a loss of $0.51, delivering a surprise of 32%.Over the last four quarters, the company has surpasse ...

Core Viewpoint - Vericel Corporation reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -155.56% [1] Financial Performance - The company posted revenues of $52.6 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.73%, compared to revenues of $51.28 million a year ago [2] - Over the last four quarters, Vericel has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Vericel shares have declined approximately 26.3% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Vericel is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $65.24 million, and for the current fiscal year, it is $0.32 on revenues of $286.96 million [7] - The estimate revisions trend for Vericel is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Vericel belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.41%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.17, delivering a surprise of 200%.Over the last four quarters, the ...

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 337.50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.37 per share when it actually produced earnings of $0.23, delivering a surprise of 162.16%.Over the ...

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.41%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.15 per share when it actually produced a loss of $1.32, delivering a ...

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.46, delivering a surprise of -21.05%.Over the last four quarters, the company ...

Company Performance - Merus N.V. reported a quarterly loss of $1.40 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.16, and compared to a loss of $0.59 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $26.49 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 238.55%, and showing a substantial increase from year-ago revenues of $7.89 million [2] - Over the last four quarters, Merus has surpassed consensus EPS estimates only once, but has topped consensus revenue estimates two times [2] Stock Outlook - Merus shares have declined approximately 6.2% since the beginning of the year, while the S&P 500 has seen a decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.16 on revenues of $18.92 million, and for the current fiscal year, it is -$4.48 on revenues of $45.11 million [7] - The estimate revisions trend for Merus is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Merus belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Nuvation Bio Inc. reported a quarterly loss of $0.16 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company generated revenues of $3.08 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 23.36%, while revenues were zero a year ago [2] - Nuvation Bio's shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Earnings Outlook - The earnings outlook for Nuvation Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $2.5 million, and for the current fiscal year at -$0.69 on revenues of $15 million [7] - The company's earnings outlook will significantly depend on management's commentary during the earnings call [2] Industry Context - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nuvation Bio's stock performance [5]